You just read:

Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome

News provided by

Kyowa Hakko Kirin Co., Ltd.

Aug 08, 2018, 12:16 ET